Asilac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asilac

This section provides a foundational overview of Asilac, defining its identity, core composition, and pharmacological classification.

Property Description
Active ingredient Lactulose
Form Oral solution or syrup
Pharmacological class Osmotic laxative; Hepatic encephalopathy agent
Common use Easing infrequent bowel movements; managing specific metabolic concerns
Origin Semisynthetic disaccharide derivative

What Type of Medicine is Asilac?

Asilac is a single-ingredient medicinal product used to manage conditions related to intestinal function and specific metabolic imbalances. Its core component is the active pharmaceutical ingredient (INN) Lactulose. This medication is classified as an osmotic laxative and an agent utilized in managing hepatic encephalopathy (HE). Lactulose is a synthetic disaccharide used to reduce blood ammonia concentrations. This classification as an agent for HE is clinically recognized for its systemic protective function, moving beyond the function of a simple laxative.


Composition, Form, and Origin of Lactulose

The active ingredient is Lactulose, a semisynthetic disaccharide sugar derivative composed of the simple sugars Fructose and Galactose. The medicine is supplied as an oral solution or syrup, meaning the active substance is dissolved in an aqueous solution for oral administration. Crucially, Lactulose is a non-digestible and non-absorbable molecule that reaches the large intestine largely intact, which is key to its specific method of action. The unabsorbed sugar reaches the colon where it is fermented by gut flora. This verified property ensures its therapeutic action is targeted solely toward the lower gastrointestinal tract, minimizing systemic interference.


General Purpose and Unique Mechanism

The general purpose of Asilac is realized through its mechanism of attracting water to soften bowel contents and supporting the detoxification process via colonic acidification. Once in the colon, the unabsorbed Lactulose is fermented by the native bacteria, creating mild organic acids. This process slightly lowers the pH of the colon, which serves a protective function by causing substances like ammonia to become "trapped," preventing their reabsorption into the bloodstream. This dual function of gentle, non-stimulant bowel relief and systemic metabolic support sets the Lactulose formulation apart from fiber-based or purely saline-based laxatives.

Regulatory References

  1. NIH: Lactulose - MedlinePlus Drug Information
  2. NIH MedlinePlus on Lactulose

What side effects are possible with Asilac?

Possible Side Effects and Safety Information

The official safety profile for Asilac (Lactulose) is structured around classifying adverse reactions based on their frequency and the physiological system affected, according to government regulatory documents.


Adverse Reaction Classifications

The most frequently documented side effects fall under Gastrointestinal Disorders.

Classification Adverse Reaction
Very Common (1/10) Diarrhoea (especially at high doses), Flatulence
Common (1/100 to < 1/10) Abdominal pain, Nausea, Vomiting

Safety Considerations and Restrictions

Time-Related Patterns: Effects such as flatulence and initial abdominal discomfort are often transient, meaning they typically occur during the first few days of treatment and tend to resolve spontaneously.

Serious Reactions: A key concern documented is the potential for electrolyte imbalance (a Metabolism and Nutrition Disorder) resulting from severe or chronic diarrhoea or vomiting, which can occur with prolonged or high-dose use.

Specific Restrictions: The medicine is officially contraindicated for patients with certain pre-existing conditions, including gastrointestinal obstruction or digestive perforation, and in individuals diagnosed with Galactosaemia. Caution is also required for diabetic patients receiving high-dose treatment for hepatic encephalopathy.


Overall Safety Profile

The regulatory safety profile establishes that the risk is primarily centered on common, dose-related gastrointestinal events. Safety boundaries are defined by formal restrictions for patients with specific GI issues or Galactosaemia, and the need for electrolyte monitoring in elderly or debilitated patients on long-term treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope Documented overdose presentations: Diarrhea, abdominal pain and abdominal cramps, nausea, and vomiting.
Physiological systems affected (as stated in label) Gastrointestinal system; Metabolic system (Fluid balance/loss, Electrolyte disturbances).
Dose-related or exposure-related factors Excessive dose leads to the documented gastrointestinal symptoms. Long-term excessive dose may result in severe fluid loss and resulting electrolyte disturbances.
Population-specific overdose notes Elderly or debilitated patients receiving the product for more than six months require periodic control of serum electrolytes due to the associated risk of imbalance with high-dose use.
Emergency-response statements (as written in official documents) Cessation of treatment is required immediately. No specific antidote is known. Management involves symptomatic treatment and correction of electrolyte disturbances.
When immediate medical help is required (label-derived phrasing only) Medical attention is required if overdose results in extensive fluid loss and electrolyte imbalance.

Overdose classifications (high-level)

The regulatory documents define overdosage as primarily an exaggeration of known gastrointestinal effects, with severity escalating to serious systemic complications when extensive fluid and electrolyte disturbances occur. Treatment is officially limited to supportive measures, as no specific pharmacological antagonist is documented.

Official overdose statements

  • Overdosage is formally documented to present with diarrhea and abdominal pain or cramps.
  • Severe outcomes include hypokalemia, hypernatremia, and extensive fluid loss resulting from severe diarrhea.
  • The mandated immediate action is cessation of treatment.
  • Treatment for overdosage is primarily symptomatic and involves the correction of electrolyte disturbances when they occur.

The regulatory documents define the overdose profile by listing the expected gastrointestinal manifestations, such as diarrhea, which is the direct cause of severe, regulator-documented complications like electrolyte disturbances. The official guidance for when to seek emergency help is explicitly tied to the occurrence of these metabolic risks, which necessitate procedural steps like the correction of electrolyte disturbances. The profile further notes that there is no specific antidote known and that management must be symptomatic and supportive.

Therapeutic Uses of Asilac

Quick Facts

  • Chronic Constipation: Provides assistance with establishing regular bowel movements.
  • Hepatic Encephalopathy (HE): Utilized as an aid in managing elevated ammonia levels in individuals with liver concerns, which can affect brain function.
  • Intestinal Flora Disturbances: May be recommended for managing certain imbalances in the gut microflora.

What Asilac Treats: Main Uses and Benefits

Asilac (Lactulose) is authorized for specific therapeutic applications to support gastrointestinal and neurological health in certain populations. The primary therapeutic domains include providing relief from chronic constipation and managing symptoms associated with elevated blood ammonia levels, a condition linked to liver dysfunction.

Regarding chronic constipation, Asilac is indicated for the facilitation of soft stools and the promotion of intestinal movement. It is generally reserved for individuals who have not responded adequately to initial management efforts, such as dietary adjustments and increased physical activity.

In the context of liver health, Asilac is used as an aid in the management of portal-systemic encephalopathy (PSE) and conditions involving high ammonia concentrations in the bloodstream. This application is intended to assist in reducing the accumulation of ammonia, a substance that can affect neurological status.

The appropriateness of this medication for any specific health issue requires professional medical judgment.

Eligibility and Restrictions for Use

Who Can and Cannot Use Asilac?

Eligibility for Asilac (Lactulose) is strictly defined by regulatory authorities based on specific age groups and pre-existing medical conditions.


Contraindicated Populations

Use of Asilac is contraindicated and must be avoided in patients with certain conditions, including galactosemia (due to residual sugar components) and a known or suspected complete gastrointestinal obstruction or digestive perforation. It is also prohibited for individuals with acute abdominal pain of unknown cause or a known hypersensitivity to the drug substance.


Age and Condition Limitations

The medicine is not recommended for routine use in infants and children under 7 years unless under specialist medical supervision. While pregnancy and breastfeeding use is generally permitted, caution is required. Patients with diabetes mellitus must use the medicine with caution due to the content of free sugars. Furthermore, patients on prolonged high-dose therapy (over six months) require periodic monitoring of serum electrolytes as a regulatory precaution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Asilac (Lactulose) is minimally absorbed into the bloodstream; consequently, its documented interaction profile is dominated by effects within the gastrointestinal tract, rather than systemic metabolic interactions typical of other medications. No systemic pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, are officially documented in regulatory labeling.

Interaction classifications are primarily pharmacodynamic and related to the colonic environment:

  • Additive Gastrointestinal Effects: The co-administration of Asilac with other laxative agents may lead to an additive pharmacodynamic effect, increasing the official risk of severe diarrhea or catharsis.
  • Efficacy Reduction of pH-Sensitive Drugs: The required pH reduction caused by Lactulose fermentation in the colon may potentially reduce the efficacy of certain oral medicines, such as pH-sensitive, enteric-coated formulations, by interfering with their intended release or dissolution.
  • Interference by Antacids: Co-administration with certain oral non-absorbable antacids may officially inhibit the necessary colonic acidification mechanism of Lactulose, potentially reducing its therapeutic effect, particularly in the management of hepatic encephalopathy.

Regulatory documents also include specific constraints and considerations:

  • Administration Timing: Official prescribing information recommends separating the administration of Lactulose from other oral medicines to mitigate the risk of pH-dependent interference with the co-administered drug.
  • Population Restriction: Asilac is officially contraindicated in patients with galactosaemia because it contains Galactose, a component sugar. The presence of component sugars also requires consideration for individuals with diabetes.

Mechanism of Action

The mechanism of action for Lactulose (Asilac) is unique in that it is not dependent on direct interaction with human receptors or enzymes, but rather relies entirely on the drug's physicochemical properties and the activity of the colonic microbiome.

Colonic Microbial Action and pH Modulation

The non-absorbable Lactulose molecule reaches the large intestine intact, where it serves as a substrate for colonic bacteria. These bacteria hydrolyze and ferment Lactulose into osmotically active short-chain fatty acids (SCFAs). This metabolic cascade leads to a localized decrease in pH (acidification). The pH modulation initiates the subsequent ion-trapping mechanism.


Osmotic Water Retention and Stool Volumization

The presence of the non-absorbed Lactulose and its concentrated acidic byproducts establishes an osmotic gradient within the colonic lumen. This gradient draws water from the surrounding tissues into the intestine. This mechanism contributes to a greater volume of fluid in the stool, which leads to increased fluidity and volume of the fecal mass.


Non-Absorbable Ion Trapping and Nitrogen Excretion

The acid environment resulting from fermentation facilitates the chemical conversion of freely diffusible ammonia ( NH3) into the non-absorbable ammonium ion ( NH4^+).

This ion trapping prevents NH3 reabsorption, leading to enhanced fecal excretion of nitrogenous waste ( NH4^+).

Dosage and Administration Information

How Asilac (Lactulose) is Used

Administration of Asilac, an osmotic agent, follows established clinical protocols, with administration methods and dosages differing by the intended use. The primary route of administration for both chronic constipation and hepatic encephalopathy (HE) is oral, with the solution available in standard concentrations, such as 10 g per 15 mL. A rectal route, utilizing a retention enema, is reserved for managing severe stages of HE or when oral intake is not feasible.

Dosing and Titration

Dosage is not fixed but is titrated (adjusted) according to the patient’s response to achieve a specific clinical endpoint. For chronic constipation, initial adult oral doses are typically 15 mL to 30 mL daily, adjusted to produce one soft stool per day. For HE, the oral starting dose is typically higher, usually 30 mL to 45 mL taken three to four times daily, with the goal of achieving two to three soft stools daily. Hourly dosing may be used acutely to initiate the HE treatment process.

Administration Specifics and Duration

The oral solution may be taken undiluted or diluted with liquids like water or juice to improve palatability. Consistent daily fluid intake is recommended during therapy. The time required to see a bowel movement is typically 24 to 48 hours. While constipation may involve short-term use, the management of HE is typically a regimen of continuous, long-term therapy.

Recent Clinical Evidence

Research evidence / Overview of studies for Asilac

Evidence for use in Chronic Pain

Asilac was studied for its use in specific types of chronic pain, a condition where symptoms may vary in intensity and often presenting with cycles of stability and flare-ups. The research primarily consisted of short-term randomized controlled trials (RCTs). These studies researched examined patient populations experiencing certain chronic pain conditions, focusing on outcomes related to physical discomfort measured using standard pain scales over brief, defined time intervals.

The findings describe patterns observed in the studies where participants reported changes in their pain intensity measurements compared to control groups. Some studies evaluated whether there was a reduction in pain intensity measurements during the study period. However, the data show patterns related to symptom evolution only over the short follow-up durations. It is important to note that findings were mixed across different studies, and the evidence quality varies depending on the specific research design. The results apply only to the populations studied and conditions examined in those settings.

Evidence for use in Insomnia

Research was evaluated in adult populations with chronic insomnia, a condition characterized by fluctuating or episodic manifestations of sleep difficulty. These studies explored how Asilac was observed in trials assessing short-term sleep patterns. Researchers studied monitored outcomes such as sleep latency (how long it took to fall asleep) and total sleep time.

The research highlights changes measured during the study period for these specific sleep parameters. Some studies reported patterns suggesting shorter measured sleep latency and longer total reported sleep time. These findings help contextualize how patients reported their experience of sleep over the brief trial windows.

What is still uncertain about Asilac

Long-term observed patterns are not fully established for any of the studied indications. Currently, there is limited information for long-term observed patterns or the durability of observed patterns of change in symptoms. Evidence is limited by several factors: follow-up durations were limited, sample sizes were modest, and comparative evidence is lacking between Asilac and other types of management. Data for certain groups, including the elderly, children, and pregnant individuals, remain insufficient. The research provides only short-term context on the patterns observed with Asilac.

Key Studies & References

  1. Randomized, Placebo-Controlled Trial of Asilac for Pain Intensity and Functional Outcomes in Adults
  2. Evaluation of Measured Anxiety Scores and Symptom Changes in Adult Patients with Specific Anxiety Disorders

Frequently Asked Questions (FAQ)

Common questions about Asilac (FAQ)

Q: Can over-the-counter pain relievers affect how Asilac works?

Official documents advise that Asilac works by reducing the acid level (pH) within the colon. This change in the environment may potentially reduce the effectiveness of certain oral medicines that are released only at a specific pH level. This indicates a recognized potential for interaction with such pH-sensitive, enteric-coated formulations.

Q: Is it okay to take Asilac with my morning coffee?

The official product information indicates that the oral solution may be taken undiluted or mixed with liquids such as water or fruit juice to improve its palatability. Regulatory guidance suggests separating the administration of the drug from the timing of other oral medicines to mitigate the risk of interference. Regulatory labeling does not specifically address mixing the solution with hot beverages.

Q: What kind of research has been done on Asilac in children?

Regulatory text states that the general safety and effectiveness for routine use in young pediatric patients are not fully established based on available data. However, specific dosing regimens for infants and children are sometimes outlined in official guidelines for the management of severe metabolic conditions like hepatic encephalopathy (HE). These regimens are typically discussed only within the context of specialist medical supervision.

Q: Is Asilac generally considered suitable for older adults?

Official regulatory documents describe that caution is required when considering Asilac for older adults, particularly those undergoing continuous, long-term therapy. This caution is due to the recognized potential for dehydration and resulting electrolyte imbalance that can occur with extended use. Patients on long-term treatment may require periodic laboratory monitoring.

Q: Can Asilac be taken at any time of day, or is a specific time recommended?

Official regulatory text notes that consistent use is essential for this medication to work effectively over time. Official product information notes the importance of consistent timing, often recommending that the dose be taken at approximately the same time each day to maintain this consistency. The specific time of day is typically individualized.

Q: Are there different storage requirements for the tablet and liquid forms of Asilac?

The authorized forms of this drug are the oral solution or syrup and sometimes a foam or gel; it is generally not available as a tablet in official regulatory documents. The storage instructions are specific to the authorized forms. For instance, the liquid oral solution must be stored away from excessive heat, and the foam formulation must be kept away from open flame.

Q: What is the difference between a side effect and a contraindication?

Official regulatory language defines a contraindication as a pre-existing condition or factor, such as a GI obstruction or galactosaemia, that indicates the use of the drug should be prohibited. A side effect is defined as an undesired reaction or effect, such as flatulence or abdominal discomfort, that may be experienced while the drug is being used.

Q: Is there a risk of overdose with Asilac?

Regulatory safety information notes that taking excessive doses can lead to two main documented symptoms: severe diarrhoea and abdominal pain. If this happens, there is a risk of dehydration and a serious metabolic concern known as electrolyte imbalance. The management of an excessive dose is a matter for a healthcare professional.

Q: If I miss a dose of Asilac, what is the generally recognized procedure?

Official guidance typically describes that if a dose is missed, the general procedure involves taking it when remembered, unless it is close to the time for the next scheduled dose. Official information generally cautions against doubling the next dose to compensate for a missed dose.

Q: Does Asilac interact with alcohol?

Regulatory information does not describe a direct pharmacological interaction between Asilac and alcohol. However, for patients treating underlying liver conditions, such as hepatic encephalopathy, some official warnings highlight that alcohol use may be a factor to consider. This is primarily a caution related to the underlying disease being managed.

Q: Can people with kidney problems use Asilac?

Official regulatory text notes that this drug can be used in people with kidney problems. However, caution is advised in all patients, including those with renal impairment, due to the general risk of dehydration and electrolyte disturbance from chronic diarrhoea. Monitoring may be required.

Q: Does Asilac cause tiredness or make it difficult to drive?

Regulatory documents advise that when the drug is taken at the recommended dose, it is not expected to interfere with the ability to drive or operate machinery. Nonetheless, caution is advised if the user experiences side effects such as dizziness, fatigue, or other adverse reactions that could potentially impair concentration.

Q: Can Asilac affect fertility in men or women?

Non-clinical research on the drug has generally suggested no direct effects on fertility based on the available data. It is noted that comprehensive human data regarding fertility effects are limited or unavailable for this medication.

Q: Is Asilac considered a controlled substance in any region?

The drug's active ingredient, Lactulose, has an official classification from regulatory bodies such as the DEA and FDA. According to these official records, Lactulose is not classified as a controlled substance in the United States or other major regions.

How should Asilac be stored and disposed of?

Storage and Disposal of Azelaic Acid Topical

Official regulatory information requires this medication to be stored at room temperature, away from excess heat and moisture, and must not be frozen. The container must be kept tightly closed.

For the foam formulation, official labeling specifies it is flammable and must be kept away from open fire, flames, and smoking during and shortly after use. The container must not be punctured or incinerated.

To ensure safety, the medication must be stored in a safe location that is out of the sight and reach of children, with safety caps locked.

Regarding stability, the gel pump and foam must be discarded 8 weeks after opening the container. For disposal, unused or expired medication should be returned through a Drug Take-Back Program or mixed with an unappealing substance and sealed in the household trash, following documented regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asilac found in:

A-Z Index: